LAYN Antibody
Description
Role in CD8+ T Cell Function
-
Antitumor Immunity: LAYN is highly expressed on clonally expanded, tumor-infiltrating CD8+ T cells (TILs) in melanoma. LAYN deletion reduces T cell adhesion via integrin αLβ2 (LFA-1), impairing tumor cell killing .
-
Dual Prognostic Impact:
Regulatory T Cell (Treg) Modulation
-
LAYN anchors Tregs in skin and tumor microenvironments, promoting immune suppression. Conditional LAYN deletion in murine Tregs reduces tumor accumulation but paradoxically accelerates tumor growth by altering Treg motility .
Mechanistic Insights
-
Integrin Activation: Layilin colocalizes with LFA-1 on T cells, augmenting integrin-mediated adhesion critical for immune synapse formation .
-
Cytotoxic Activity: CRISPR-Cas9 knockout of LAYN in human CD8+ T cells reduces tumor cell lysis by 30–50% in antigen-specific models .
Technical Validation Data
Clinical and Therapeutic Implications
-
Biomarker Potential: LAYN expression stratifies patient outcomes in melanoma (favorable) vs. HCC (unfavorable) .
-
Therapeutic Targeting: Blocking LAYN in HCC partially restores CD8+ T cell function, suggesting context-dependent therapeutic strategies .
Limitations and Controversies
Product Specs
PAT20G8AT
Anti-human LAYN mAb, clone PAT20G8AT, is derived from hybridization of mouse F0 myeloma cells with spleen cells from BALB/c mice immunized with a recombinant human LAYN protein 22-235 amino acids purified from E. coli.
Mouse IgG2b Kappa.
Product Science Overview
Recent research has highlighted the importance of Layilin in regulatory T cells (Tregs). Tregs are a subset of CD4+ T cells that play a crucial role in maintaining immune homeostasis. Layilin is preferentially and highly expressed on a subset of activated Tregs in both healthy and diseased human skin . The expression of Layilin on Tregs is induced by TCR-mediated activation in the presence of IL-2 or TGF-β .
Layilin facilitates the adhesion of Tregs in the skin, which limits their suppressive capacity. This anchoring effect on Treg dynamic motility in vivo suggests that reduced Treg motility acts to limit immune regulation in nonlymphoid organs . This unique mechanism may guide strategies to exploit this phenomenon for therapeutic benefit.
Mouse anti-human Layilin antibodies are developed for various scientific applications, including Western Blot, ELISA, Immunohistochemistry, Flow Cytometry, and Immunocytochemistry . These antibodies target Layilin in human, mouse, and rat samples and are available in polyclonal, monoclonal, and recombinant monoclonal forms .
